Citi Upgrades Horizon Pharma (HZNP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BMO Sees Favorable Risk/Reward for Horizon Pharma (HZNP) Ahead of phase 3 Data for Actimmune in FA
November 28, 2016 6:56 AM ESTBMO Capital analyst Gary Nachman sees favorable risk/reward for Horizon Pharma (NASDAQ: HZNP) into Phase 3 data for Actimmune in Friedreich's Ataxia (FA).
Nachman commented, "ased on feedback from ataxia specialists that we include in the note and considering how HZNP... More
